Nitrosamine drug substance-related impurities (NDSRIs) continue to be a primary regulatory focus for health authorities worldwide including US FDA, EMA, and CDSCO. Under the Carcinogenic Potency Categorization Approach (CPCA), risk assessors must evaluate the alpha-hydrogen substitution and electronic environment surrounding the nitroso functional group.
### Key Analytical Considerations
1. **High Sensitivity LC-MS/MS & GC-MS/MS Methods**: Developing validated quantitative assays with lower limits of quantitation (LLOQ) reaching sub-ppm levels (typically 0.03 ppm or lower based on maximum daily dose).
2. **Isotope-Labelled Internal Standards**: Utilizing deuterated or 13C-labelled analogues (e.g., NDEA-d10, NDMA-d6) to eliminate matrix suppression effects and guarantee peak accuracy.
3. **Confirmatory Orthogonal Techniques**: Employing high-resolution mass spectrometry (HRMS) to rule out isobaric interferences in complex finished drug matrices.
At Karpschem, every nitrosamine reference standard is accompanied by an extensive Certificate of Analysis (COA) specifying certified chromatographic purity, spectroscopic structure confirmation (1H, 13C NMR), and HRMS verification.